Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 19 Carcinoma, Non-Small-Cell Lung 15 Lung Neoplasms 13 Urinary Bladder Neoplasms 11 Ovarian Neoplasms 8 Non-Muscle Invasive Bladder Neoplasms 6 Neoplasm Metastasis 5 Colorectal Neoplasms 5 Cholangiocarcinoma 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Lymphoma, Large B-Cell, Diffuse 4 Fallopian Tube Neoplasms 4 Breast Neoplasms 4 Biliary Tract Neoplasms 4 Triple Negative Breast Neoplasms 3 Nasopharyngeal Carcinoma 3 Melanoma 3 Recurrence 2 Rectal Neoplasms 2 Osteosarcoma 2 Lymphoma, Follicular 2 Gallbladder Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Transitional Cell 2 Bile Duct Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urologic Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Gemcitabine × 30 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡